Real World Medicines Monitoring: MSH Project Launches New Tool for Improved Pharmacovigilance at #WCLH2015

Real World Medicines Monitoring: MSH Project Launches New Tool for Improved Pharmacovigilance at #WCLH2015

{Photo credit: Warren Zelman}Photo credit: Warren Zelman

This week, at the 46th Union World Conference on Lung Health (hashtag ), the US Agency for International Development (USAID)-funded and Management Sciences for Health (MSH)-led, Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program is launching a new tool to improve how the safety and effectiveness of medicines is monitored in low- and middle-income countries.

All medicines undergo rigorous clinical testing prior to being made publicly available. Continuing to monitor the safety and effectiveness of medicines in real world settings, also referred to as pharmacovigilance, is critically important to ensure that medicines can be used over a prolonged period of time, in conjunction with other medicines, among new patient populations, and in patients with multiple illnesses. 

Low- and middle-income countries, however, often lack the resources, capacity, and systems required to effectively implement pharmacovigilance activities. They often rely heavily on passive reporting methods which can underestimate potential medicines use issues.

One common challenge is the lack of available data collection and analysis tools needed for active pharmacovigilance. To help address this barrier, SIAPS developed a web-based application to streamline and simplify the data collection and analysis process, known as the Pharmacovigilance Monitoring System (PViMS).

The only free software of its kind customized for use in low resource settings, PViMS helps clinicians, regulatory authorities, program managers, and other implementing partners collect, analyze, and monitor adverse reactions associated with the use of medicines, including those used to treat tuberculosis (TB). In addition to improving documentation and reporting of adverse drug events, PViMS can also be used to alert program managers to potential problems by flagging medicines use issues for further evaluation.

With PViMS, regulatory authorities, program managers, physicians, and pharmacists have a tool which helps to ensure that the medicines they provide to mothers and their children are not only safe and effective, but also help them attain the best possible health outcomes.

For more information on PViMS, visit the SIAPS website, contact our team, or, if you’re attending the Union World Conference on Lung Health, stop by the MSH booth () for a live demonstration of PViMS.

A version of this post originally appeared on the SIAPS website.

Learn more about MSH and SIAPS at here; on Facebook, follow MSH and SIAPS, and on Twitter and with hashtags  and .

Add new comment

Printer Friendly VersionPDF